The pharmaceutical formulations include solid dosage forms of tablets and hard capsules.
The products will be manufactured at the aforementioned facility located at Verna Industrial Estate, Verna, Goa, and marketed & distributed in Australian markets through the company’s subsidiary Nova Pharmaceuticals Australasia.
Marksans Pharma is primarily engaged in the business of research, manufacture, marketing, and sale of pharmaceutical formulations.
The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24.